The FDA sent 40 per cent more GMP warning letters to biopharma facilities outside the US in fiscal 2011 than the previous year. In the last fiscal year, ended March 31, the US Food and Drug Administration (FDA) sent warning letters relating to drug manufacturing and quality to 52 facilities, more than half of which targeted overseas plants.
